原发小细胞肺癌中BRAF/KRAS以及PIK3CA突变的基因特征及临床特征

doi:10.3760/cma.j.issn.1004-4221.2018.09.003

摘要
图/表
参考文献()
相关文章 (10)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的在中国人群小细胞肺癌(SCLC)标本中检测BRAF/KRAS以及PIK3CA基因突变频率,分析这些基因突变的基因特征和临床特征。方法 2009-2014年共收集557例单纯SCLC患者组织样本。利用双脱氧测序法进行BRAF、KRAS、PIK3CA、NRAS、MEK1基因突变检测。χ²检验分析临床因素与基因突变的相关性,Kaplan-Meier法生存分析,Cox模型多因素预后分析。结果在557例标本中检测到13例BRAF突变,突变类型包括V600E (n=5)、V600A (n=2)、V600M (n=1)、D594G (n=1)、G464E (n=1)、K601R (n=2)、S605N (n=1)。6例KRAS突变,突变类型包括G12C (n=3)、G12A (n=1)、G12D (n=1)、G13D (n=1)。4例PIK3CA突变,突变类型包括E545G (n=2)、H1047R (n=2)。另外1例NRAS突变(Q61R)和1例MEK1突变(D61Y)。这些突变基因与患者年龄、性别、吸烟状态、临床分期均无相关性。单因素生存分析结果显示基因突变组患者的生存时间比无此类突变者生存时间差,中位生存时间分别为(10.30±0.75)个月(95%CI为8.83~11.77个月)和(12.80±0.54)个月(95%CI为11.74~13.86)(P=0.011)。结论在单纯SCLC中存在小比例的BRAF/KRAS、PIK3CA基因突变群体,这些基因突变与患者的临床特征无明显统计学相关性,但单因素生存分析显示与患者生存预后呈负相关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：小细胞肺癌, BRAF基因, KRAS基因, PIK3CA基因, 基因突变

Abstract：Objective To detect the frequency of BRAF/KRAS and PIK3CA mutations in the small cell lung cancer (SCLC) specimens from a large population of Chinese patients and to analyze the gene mutation and clinical characteristics. Methods A total of 557 samples were collected from SCLC patients from 2009 to 2014.BRAF,KRAS,PIK3CA,NRAS and MEK1 gene mutations were detected by the dideoxy sequencing. Chi-square test was adopted to analyze the correlation between clinical factors and gene mutation. Kaplan-Meier method was utilized for survival analysis. Cox model was used for multivariate prognostic analysis. Results BRAF mutations were detected in 13 out of 557 specimens. The mutation types included V600E (n=5),V600A (n=2),V600M (n=1),D594G (n=1),G464E (n=1),K601R (n=2) and S605N (n=1).KRAS mutation was detected in 6 cases including G12C (n=3),G12A (n=1),G12D (n=1) andG13D (n=1).PIK3CA mutation was observed in 4 samples including E545G (n=2) and H1047R (n=2).Besides,NRAS mutation (Q61R) was detected in 1 case and MEK1 mutation(D61Y) was noted in 1 case. These gene mutations were not significantly correlated with the age,gender,smoking status and clinical staging of the patients. Univariate survival analysis demonstrated the median survival time of patients with gene mutation was (10.30±0.751) months (95%CI:8.829-11.771 months),significantly shorter than (12.80±0.543) months (95%CI:11.736-13.864 months) of their counterparts without gene mutation (P=0.011). Conclusions BRAF/KRAS and PIK3CA gene mutation is detected in a small proportion of SCLC patients. These gene mutations are not significantly correlated with the clinical characteristics. Univariate survival analysis demonstrates that negative these gene mutations are negatively correlated with the clinical prognosis of SCLC patients.

Key words： Small cell lung cancer BRAF gene KRAS gene PIK3CA gene Gene mutation

收稿日期: 2017-08-30

基金资助:国家自然科学基金项目(81401911、81672972、81402540);浙江省博士后科研项目择优资助项目(BSH1402064)

通讯作者: 陈明,Email:chenming@zjcc.org.cn;张建军,Email:JZhang20@mdanderson.org

引用本文:

. 原发小细胞肺癌中BRAF/KRAS以及PIK3CA突变的基因特征及临床特征[J]. 中华放射肿瘤学杂志, 2018, 27(9): 805-808.

. BRAF/KRAS and PIK3CA mutation characteristics and clinical significance in primary small cell lung caner[J]. Chinese Journal of Radiation Oncology, 2018, 27(9): 805-808.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2018.09.003 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2018/V27/I9/805

[1] Rudin CM,Durinck S,Stawiski EW,et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer[J].Nat Genet,2012,44(10):1111-1116.DOI:10.1038/ng.2405.
[2] Peifer M,Fernández-Cuesta L,Sos ML,et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer[J].Nat Genet,2012,44(10):1104-1110.DOI:10.1038/ng.2396.
[3] George J,Lim JS,Jang SJ,et al. Comprehensive genomic profiles of small cell lung cancer[J].Nature,2015;524(7563):47-53.DOI:10.1038/ng.2405.
[4] Jiang L,Huang J,Higgs BW,et al. Genomic landscape survey identifies srsf1 as a key oncodriver in small cell lung cancer[J/OL].PLoS Genet,2016,12(4):e1005895.DOI:10.1371/journal.pgen.1005895.
[5] Ross JS,Wang K,Elkadi OR,et al. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer[J].J Clin Pathol,2014,67(9):772-776.DOI:10.1136/jclinpath-2014-202447.
[6] Nguyen-Ngoc T,Bouchaab H,Adjei AA,et al. BRAF alterations as therapeutic targets in non-small-cell lung cancer[J].J Thorac Oncol,2015,10(10):1396-403.DOI:10.1097/JTO.0000000000000644.
[7] Caparica R,de Castro G Jr,Gil-Bazo I,et al. BRAF mutations in non-small cell lung cancer:has finally Janus opened the door?[J].Crit Rev Oncol Hematol,2016,101(1):32-39 DOI:10.1016/j.critrevonc.2016.02.012.
[8] Paik PK,Arcila ME,Fara M,et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations[J].J Clin Oncol,2011,29(15):2046-2051.DOI:10.1200/JCO.2010.33.1280.
[9] Marchetti A,Felicioni L,Malatesta S,et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations[J].J Clin Oncol,2011,29(26):3574-3579.DOI:10.1200/JCO.2011.35.9638.
[10] Litvak AM,Paik PK,Woo KM,et al. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers[J].J Thorac Oncol,2014,9(11):1669-1674.DOI:10.1097/JTO.0000000000000344.
[11] Chapman PB,Hauschild A,Robert C,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation[J].N Engl J Med,2011,364(26):2507-2516.DOI:10.1056/NEJMoa1103782.
[12] Hauschild A,Grobb J,Demidov L,et al.1092Pdan update on overall survival (OS) and follow-on therapies in break-3,a phase Ⅲ,randomized trial:dabrafenib (D) vs.dacarbazine (DTIC) in patients (PTS) with braf v600e mutation-positive metastatic melanoma (MM)[J].Ann Oncol,2014,25(Suppl_4):iv378.
[13] Hyman DM,Puzanov I,Subbiah V,et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J].N Engl J Med,2015,373(8):726-736.DOI:10.1056/NEJMoa1502309.
[14] Planchard D,Kim TM,Mazieres J,et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer:a single-arm,multicentre,open-label,phase 2 trial[J].Lancet Oncol,2016,17(5):642-650.DOI:10.1016/S1470-2045(16)00077-2.
[15] Wakuda K,Kenmotsu H,Serizawa M,et al. Molecular profiling of small cell lung cancer in a Japanese cohort[J].Lung Cancer,2014,84(2):139-144.
[16] Roberts PJ,Stinchcombe TE.KRAS mutation:should we test for it,and does it matter?[J].J Clin Oncol,2013,31(8):1112-21.DOI:10.1200/JCO.2012.43.0454.
[17] Wood K,Hensing T,Malik R,et al. Prognostic and predictive value in KRAS in non-small-cell lung cancer:a review[J].JAMA Oncol,2016,2(6):805-812.DOI:10.1001/jamaoncol.2016.0405.
[18] Guin S,Ru Y,Wynes MW,et al. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression[J].J Thorac Oncol,2013,8(12):1492-1501.DOI:10.1097/JTO.0000000000000007.
[19] Suda K,Tomizawa K,Mitsudomi T.Biological and clinical significance of KRAS mutations in lung cancer:an oncogenic driver that contrasts with EGFR mutation[J].Cancer Metast Rev,2010,29(1):49-60.DOI:10.1007/s10555-010-9209-4.
[20] Umemura S1,Mimaki S,Makinoshima H,et al. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis[J].J Thorac Oncol,2014,9(9):1324-1331.DOI:10.1097/JTO.0000000000000250.